RIAD, Abanoub, Ave POLD, Elham KATEEB and Sameh ATTIA. Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports. Frontiers in Public Health. Lausanne: Frontiers, 2022, vol. 10, July 2022, p. 1-14. ISSN 2296-2565. Available from: https://dx.doi.org/10.3389/fpubh.2022.952781.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports
Authors RIAD, Abanoub (818 Egypt, belonging to the institution), Ave POLD (203 Czech Republic), Elham KATEEB and Sameh ATTIA (guarantor).
Edition Frontiers in Public Health, Lausanne, Frontiers, 2022, 2296-2565.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30304 Public and environmental health
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.200
RIV identification code RIV/00216224:14110/22:00126236
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3389/fpubh.2022.952781
UT WoS 000830988400001
Keywords in English anaphylaxis; COVID-19 vaccines; drug-related side effects and adverse reactions; oral manifestations; pharmacovigilance oral adverse events following COVID-19 vaccination 2
Tags 14110525, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 5/4/2023 08:16.
Abstract
Background: Oral adverse events (AEs) following COVID-19 vaccination have been sporadically reported during the previous months, warranting further investigation for their prevalence and suspected relationship with vaccine-elicited immune response. Methods: A retrospective analysis using the Vaccine Adverse Event Reporting System (VAERS) data was conducted to evaluate AEs within the oral cavity (mucosa, tongue, lips, palate, dentition, salivary glands) and AEs involving taste and other sensations. Oral AEs reported after receiving COVID-19 vaccination (test group) and seasonal influenza vaccination (control group) were extracted and cross-tabulated to assess their relative prevalence. Results: Among the 128 solicited (suspected) oral AEs, oral paresthesia (0.872%) was most reported after receiving COVID-19 vaccines, followed by the swelling of lips (0.844%), ageusia (0.722%), oral hypoesthesia (0.648%), swollen tongue (0.628%), and dysgeusia (0.617%). The reported prevalence of oral AEs was higher in the COVID-19 vaccine group than in the seasonal influenza group. The distribution pattern of the most reported oral AEs was similar for both COVID-19 and seasonal influenza vaccines. Female sex, older age (>39 years old), primer doses, and mRNA-based COVID-19 vaccines exhibited a higher reported prevalence of oral AEs. Conclusion: Within the limitations of this study, COVID-19 vaccines were found to be associated with rare oral AEs that are predominantly similar to those emerging following seasonal influenza vaccines. The most commonly reported oral AEs were oral paraesthesia (mouth-tingling), lip swelling, and ageusia, representing various pathophysiologic pathways that remain unclear. Taste-related AEs should be acknowledged in the context of the COVID-19 pandemic and the public should be adequately informed about a potential taste dysfunction after receiving the COVID-19 vaccination. Dentists and dental teams need to be aware of the prevalence, severity, and prognosis of oral AEs to inform their patients and increase public confidence in vaccines.
Links
EF19_073/0016943, research and development projectName: Interní grantová agentura Masarykovy univerzity
MUNI/A/1402/2021, interní kód MUName: Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu IV
Investor: Masaryk University
MUNI/IGA/1104/2021, interní kód MUName: COVID-19 Vaccines Safety Tracking in the Czech Republic (Acronym: CoVaST-CZ)
Investor: Masaryk University
PrintDisplayed: 21/5/2024 20:48